Factor VII TRIZ Cases

Targeted constant-region pI shifts separate heterodimers from homodimers by ion exchange while helping extend antibody serum half-life.

A chimeric FVIII-VWF protein uses a short XTEN linker and selected VWF domains to extend half-life and reduce dosing frequency in hemophilia A.

Liver-targeted AAV delivery of codon-optimized ATP7B lowers circulating copper and may provide lasting Wilson's disease correction.

A covalently linked FVIII and VWF fragment blocks endogenous VWF binding to extend FVIII half-life and reduce dosing frequency in hemophilia A.

Specific FVIII mutations such as N2118Q and B-domain deletion reduce immunogenicity while improving expression, secretion, and vector packaging.

Charge-shifted IgG1 constant regions create pI gaps that separate heterodimers from homodimers and can also extend serum half-life.

Specific Factor VIII amino acid substitutions boost secretion and clotting activity, enabling lower vector doses for hemophilia A treatment.

A TRIS-free buffer with sucrose, surfactant, and salt helps lentiviral vectors resist freeze-thaw, agitation, and temperature stress.

Cell-free synthesis from nicked closed-ended DNA enables strand-specific single-stranded AAV vectors with higher purity and expanded transgene capacity.

A two-step affinity and anion exchange purification route improves chimeric FVIII purity and activity despite low expression and pH sensitivity.

Single-domain antibodies targeting the VWF D′D3 domain help clotting factor chimeras stay in circulation longer and reduce dosing frequency.

Engineered IDLVs use nuclease sites and homology arms to insert multi-kb sequences precisely with lower toxicity in stem cells.

Codon-optimized liver-targeted lentiviral FVIII vectors enable stable hepatocyte integration and higher plasma activity at lower doses.

ECM-binding peptides retain cytokines in tumor tissue, improving local therapeutic effect while limiting systemic toxicity and side effects.

Distinct constant-region pIs let charge-based methods separate IgG1 heterodimers from homodimers while supporting longer serum half-life.

Genetically modified CALLAR T cells target B cells producing Factor VIII inhibitors to sustain titer reduction and lower bleeding risk.

Cell-targeted promoter sequences sustain therapeutic FVIII expression while limiting immune responses and anti-FVIII antibodies in hemophilia A.

A truncated VWF lacking D4-C6 domains stabilizes factor VIII while preserving multimer formation and platelet capture for VWD and haemophilia.

Targeted nuclease and donor-template integration at the albumin locus enables stable Factor VIII liver expression to improve blood clotting.

Shortened piggyBac ITRs remove repetitive sequence regions to improve plasmid stability and transposition for ex vivo and in vivo gene delivery.

Compact liver-specific promoters boost hepatic transgene expression within AAV cargo limits, helping lower vector dose and immune response.

Synthetic RNA fragments with dimerization domains and splice junctions reconstitute full-length proteins beyond AAV cargo limits.

Alternative nucleophilic catalysts replace aniline in oxime-linked polymer conjugation to improve therapeutic protein safety, cost, and efficiency.

Endemic anti-AAV5 antibodies need not block treatment when AAV5 dosing and capsid design preserve transduction and broaden patient eligibility.

Mutated recombinant GPIbα polypeptides improve vWF binding assays by reducing interference and enabling more precise vWD diagnosis.

Optimized anti-albumin sdAbs improve human and murine albumin binding to extend circulation and sustain VWF and FVIII levels in vivo.

Engineered DNA cassettes in lipid or biocompatible carriers enable repeat dosing of Factor VIII while avoiding AAV size limits and immunogenicity.

AAV6 liver-targeted Factor VIII gene delivery enables sustained clotting activity, reducing bleeding episodes and frequent infusions.

Diatomite-assisted salt precipitation prevents impeller fouling during factor XIII purification, improving yield, purity, and scale-up.

pI-shifted IgG1 constant regions enable ion exchange separation of heterodimers from homodimers while extending serum half-life.

Reconstituted spray-dried human plasma enables cold ethanol fractionation without frozen storage while preserving protein activity.

The case combines sub-7.0 kb AAV Factor VIII vectors with enhanced regulatory elements to support complete packaging and high expression.

Endothelial-specific Stabilin-2 promoter sequences drive sustained FVIII expression while reducing immune responses in hemophilia A gene therapy.

An AAV vector delivers functional ATP7B to liver cells, lowering circulating copper and reducing reliance on lifelong chelation.

Minicircle DNA delivery with a linker peptide raises FVIII expression while supporting repeat dosing and long-term Hemophilia A treatment.

Zwitterionic polymers conjugated to Factor VIII extend in vivo half-life to at least 20 hours while preserving therapeutic efficacy.

Promoters, splice junctions, and linked protein segments enable full-length protein production when large genes exceed AAV cargo limits.

Combining FVIII fusion partners with branched polyalkylene glycol addresses short half-life while maintaining coagulation activity.

Measure plasma kallikrein activation by incubating plasma with FXIIa and detecting intact and cleaved HMWK through Western blot analysis.

Lentiviral delivery into adipocytes and B-domain changes tune N-linked glycosylation and furin recognition to improve FVIII secretion.

A VWF D′/D3 segment and XTEN linker under 288 amino acids help extend FVIII half-life while addressing added molecular size and complexity.

Removing the viral capsid addresses AAV packaging limits and immune barriers while supporting repeatable, titratable FVIII delivery.

Codon optimization changes FVIII-BDD nucleotide usage to increase expression and protein production in gene therapy vectors.

Targeted insertion at the β2M locus helps engineered B cells produce therapeutic proteins while preserving sufficient β2M function.

Learn how engineered meganucleases target HBV 11-12 to improve cleavage specificity and reduce off-target cutting in host genomes.

Codon-optimized AAV vectors deliver Factor VIII through liver-specific expression to support sustained hemophilia A treatment with fewer administrations.

TRIS-free phosphate or histidine buffers with sucrose, surfactants, and NaCl help preserve lentiviral vector potency during handling.

FVIII-Fc formulation combines stabilizing excipients with extended activity to reduce dosing frequency and maintain protection from bleeding episodes.

Engineered non-AAV ITRs help expand therapeutic gene cassettes beyond AAV packaging limits while sustaining expression and reducing immune barriers.

This case combines targeted FVIII mutations to resist APC cleavage and A2-domain dissociation, improving clot formation and stability.

FVIII-Fc fusion combines clotting activity with extended circulation to reduce injections and inhibitory immune responses.

Chimeric polypeptides use force sensor cleavage domains to autonomously modulate cellular processes upon binding specific partners.

C1 and C2 domain substitutions in Factor VIII variants reduce LRP binding to prolong circulatory half-life while maintaining coagulant activity.